Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Evelo Biosciences, Inc. EVLO
$0.13
+$0 (0.23%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
15419270.00000000
-
week52high
3.29
-
week52low
0.02
-
Revenue
0
-
P/E TTM
0
-
Beta
1.26489600
-
EPS
-1.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 авг 2022 г. |
| Chardan Capital | Buy | Buy | 15 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 02 ноя 2021 г. |
| Chardan Capital | Buy | Neutral | 01 ноя 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 23 июн 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| Chardan Capital | Neutral | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Plinio Mark D. | A | 3750 | 1250 | 31 янв 2023 г. |
| CARRIERE STEPHEN J | D | 203 | 151 | 23 янв 2023 г. |
| CARRIERE STEPHEN J | D | 1063 | 354 | 19 янв 2023 г. |
| CARRIERE STEPHEN J | A | 354 | 354 | 19 янв 2023 г. |
| Thorell Marella | A | 440000 | 440000 | 01 сент 2022 г. |
| Plinio Mark D. | A | 2500 | 1250 | 29 июл 2022 г. |
| Char Daniel | A | 40000 | 40000 | 19 июл 2022 г. |
| Zung Jonathan B. | A | 115000 | 115000 | 19 июл 2022 г. |
| Epstein David R | D | 0 | 2874 | 30 июн 2022 г. |
| Epstein David R | A | 93932 | 2874 | 30 июн 2022 г. |
Новостная лента
Discover the Top Penny Stock Technical Indicators By Effectiveness
PennyStocks
28 апр 2023 г. в 06:00
Use these technical indicators to profit with penny stocks The post Discover the Top Penny Stock Technical Indicators By Effectiveness appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
InvestorPlace
27 апр 2023 г. в 08:01
Evelo Biosciences (NASDAQ: EVLO ) stock is on the rise Thursday after the company said it's shifting focus toward extracellular vesicle (EV) development. With this news, Evelo Biosciences will put a greater focus on EDP2939, which is its first EV treatment.
Evelo Biosciences, Inc. (EVLO) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 11:24
Evelo Biosciences, Inc. (NASDAQ:EVLO ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Shamira Shariffudin - Director Business Development Simba Gill - Chief Executive Officer Mark Bodmer - Chief Scientific Officer Marella Thorell - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Gospel Enyindah-Asonye - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Peyton Bohnsack - Cowen Operator Good morning and welcome to the Evelo Biosciences Conference Call to discuss its Fourth Quarter and Full Year 2022 Financial Results and Business Update. [Operator Instructions] Please be advised this call is being recorded at the company's request.
Forget Bargain Hunting, Buy 4 Stocks With Rising P/E
Zacks Investment Research
16 мар 2023 г. в 08:28
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include James River Group (JRVR), MakeMyTrip Limited (MMYT), Evelo Biosciences (EVLO) and The Kroger Co. (KR).
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
GlobeNewsWire
09 мар 2023 г. в 06:00
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights.